title: Antibody-based therapeutics in oncology.
abstract: The recent clinical and commercial success of anticancer antibodies, such as rituximab (Rituxan) and trastuzumab (Herceptin) has created great interest in antibody-based therapeutics for hematopoietic malignancies and solid tumors. Given the likely lower toxicity for antibodies versus small molecules, the potential increase in efficacy by conjugation to radioisotopes and other cellular toxins and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, it is anticipated that current and future antibody therapeutics will find substantial roles alone and in combination therapy strategies for the treatment of patients with cancer. It is also likely that conjugation strategies will add new radiolabeled and toxin-linked products to the market to complement the recent approvals of ibritumomab tiuxetan (Zevalin) and gemtuzumab ozogamycin (Mylotarg). However, although there are a large number of agents in both early and later stages of clinical development, only a handful will make it through regulatory approval and become successful products. This review considers the structure of anticancer therapeutic antibodies, the techniques used to reduce their antigenicity, factors that influence efficacy and toxicity, conjugation with isotopes and toxins and antibody target validation.
authors.affiliation: Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. rossj@mail.amc.edu
authors.forename: Jeffreys
authors.initials: J
authors.lastname: Ross
authors.forename: Karen
authors.initials: K
authors.lastname: Gray
authors.forename: David
authors.initials: D
authors.lastname: Schenkein
authors.forename: Barry
authors.initials: B
authors.lastname: Greene
authors.forename: Gary S
authors.initials: GS
authors.lastname: Gray
authors.forename: Jeanine
authors.initials: J
authors.lastname: Shulok
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Worland
authors.forename: Abbie
authors.initials: A
authors.lastname: Celniker
authors.forename: Mark
authors.initials: M
authors.lastname: Rolfe
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins